ZyVersa Therapeutics Accounts Payable

ZyVersa Therapeutics posts a accounts payable of $10M as of March 2026. That compares with $9.6B in the prior-year period — down 99.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, ZyVersa Therapeutics's accounts payable was $9.6B. The latest reading is $10M — a 99.9% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Accounts Payable is one piece of ZyVersa Therapeutics's financial statement story. At $10M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ZVSA's accounts payable usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; ZyVersa Therapeutics's other metric pages and overview cover the third.